argenex (NASDAQ:ARGX) Announces Quarterly Earnings Results

argenex (NASDAQ:ARGX) announced its quarterly earnings data on Thursday. The company reported $5.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.79 by ($0.27), FiscalAI reports. The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.44 billion. argenex had a net margin of 30.42% and a return on equity of 38.51%.

Here are the key takeaways from argenex’s conference call:

• argenx reported strong Q1 results with product net sales of $1.3 billion (63% YoY), an operating profit of $394 million, and a cash balance of $4.9 billion, supporting margin expansion and continued investment in growth.
• Commercial momentum for VYVGART remains strong — Q1 new patient starts were among the highest since launch, the medicine is the #1 prescribed biologic in gMG, the prefilled syringe materially increased demand, and a PDUFA for seronegative MG is imminent with ocular and pediatric expansions planned.
• The company is advancing its second product, empasiprubart, toward a pivotal readout expected in 4Q and argues C2-targeting could offer clinical advantages across CIDP/MMN and other complement-driven indications, positioning a second launch to deepen neuromuscular leadership.
• argenx is broadening its pipeline and sourcing strategy — five clinical-stage molecules (including phase III–ready ARGX‑213 and an oral FcRn collaboration), a China entity, and targeted strategic investments to sustain long-term growth and indication expansion.
• Near-term headwinds and risks include seasonal Q1 QoQ softness, rising competition (C5 inhibitors, other newcomers and potential head‑to‑head trials) largely in refractory settings, payer barriers to earlier-line adoption, and the need for disease awareness to access underdiagnosed populations like IMNM.

argenex Price Performance

Shares of NASDAQ ARGX traded down $5.14 during trading on Friday, hitting $782.17. 353,760 shares of the company were exchanged, compared to its average volume of 360,148. The company has a market cap of $48.64 billion, a price-to-earnings ratio of 40.07, a PEG ratio of 1.33 and a beta of 0.46. argenex has a 1 year low of $510.05 and a 1 year high of $934.62. The firm’s fifty day moving average price is $755.88 and its 200 day moving average price is $817.54.

Wall Street Analyst Weigh In

ARGX has been the topic of several recent research reports. HC Wainwright boosted their price objective on shares of argenex from $915.00 to $940.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Zacks Research raised shares of argenex from a “strong sell” rating to a “hold” rating in a research note on Friday, February 20th. Citigroup dropped their price objective on shares of argenex from $1,124.00 to $1,091.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Royal Bank Of Canada dropped their price objective on shares of argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a research note on Friday, February 27th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $1,017.78.

Institutional Investors Weigh In On argenex

Several institutional investors have recently made changes to their positions in ARGX. Invesco Ltd. boosted its position in shares of argenex by 390.4% during the 4th quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock worth $350,178,000 after purchasing an additional 331,489 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of argenex by 80.1% during the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after purchasing an additional 324,653 shares in the last quarter. Two Sigma Investments LP boosted its position in shares of argenex by 570.3% in the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after buying an additional 250,278 shares in the last quarter. Corient Private Wealth LLC boosted its position in shares of argenex by 12,441.8% in the 4th quarter. Corient Private Wealth LLC now owns 246,572 shares of the company’s stock worth $207,355,000 after buying an additional 244,606 shares in the last quarter. Finally, Woodline Partners LP boosted its position in shares of argenex by 320.8% in the 3rd quarter. Woodline Partners LP now owns 169,476 shares of the company’s stock worth $124,999,000 after buying an additional 129,205 shares in the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Major sell-side upgrades lifted sentiment — Guggenheim raised its price target to $1,135 and kept a Buy rating, calling for sizable upside from current levels. Read More.
• Positive Sentiment: Wells Fargo also bumped its target to $1,260 and assigned an Overweight rating, another strong vote of confidence from analysts that supports higher share valuations. Read More., Read More.
• Positive Sentiment: Several outlets framed the Q1 release as a profitability beat or “solid print,” highlighting strong margins and net income features that investors read as validation of argenx’s commercial execution. Read More., Read More., Read More.
• Neutral Sentiment: Leadership update: the Board appointed Karen Massey as CEO and Tim Van Hauwermeiren as Chair — a governance/strategy development that can aid execution but is a medium-term catalyst. Read More.
• Neutral Sentiment: Investor outreach: CEO to present at the BofA Health Care Conference on May 12 — provides a near-term forum for management to reinforce guidance and commercial progress. Read More.
• Neutral Sentiment: Full Q1 materials and earnings-call transcript are available for detail review (useful for investors parsing adjusted vs. GAAP metrics). Read More., Read More.
• Negative Sentiment: Key reported figures show some misses versus consensus — MarketBeat notes Q1 EPS of $5.52 (consensus $5.79) and revenue $1.31B (consensus $1.44B). Those topline and per-share shortfalls could limit upside unless management’s adjusted metrics or guidance justify current multiples. Read More.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.